GlassScriptPhysician profile
Michael B Stierstorfer
NPI 1376549360
$11,365.21
in general payments reported to CMS, 2019-2025
24 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $34.98 · 2021: $2,094 · 2022: $643 · 2023: $1,732 · 2024: $4,023 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,078 · Consulting Fee: $2,600 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,077.53 |
| Consulting Fee | $2,600.00 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $5,228.38 | 2019-2025 | Klisyri, Seysara |
| Janssen Biotech, INC. | $1,130.73 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $680.48 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $552.82 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $534.46 | 2019-2025 | Dupixent |
| Abbvie INC. | $502.32 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $383.39 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $372.36 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $331.90 | 2019 | |
| Galderma Laboratories, L.P. | $210.13 | 2019-2025 | Nemluvio |
| Ucb, INC. | $207.53 | 2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $207.21 | 2022-2024 | Sotyktu |
| Amgen INC. | $188.81 | 2023-2024 | Otezla |
| Organon LLC | $131.86 | 2025 | Vtama |
| Celgene Corporation | $124.72 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $122.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $116.11 | 2019 | |
| Arcutis Biotherapeutics, INC. | $93.74 | 2023 | |
| Pfizer INC. | $68.00 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $65.65 | 2021 | |
| Verrica Pharmaceuticals INC. | $44.48 | 2023-2024 | Ycanth |
| Prugen, INC. Pharmaceuticals | $34.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2024 | Cyltezo |
| Genzyme Corporation | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stierstorfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.